Performance of QuantaMatrix Microfluidic Agarose Channel system integrated with mycobacteria growth indicator tube liquid culture
- PMID: 34328537
- DOI: 10.1007/s00253-021-11446-0
Performance of QuantaMatrix Microfluidic Agarose Channel system integrated with mycobacteria growth indicator tube liquid culture
Abstract
The QuantaMatrix Microfluidic Agarose Channel (QMAC) system was used for rapid drug susceptibility testing (DST). Here, we performed DST using QMAC integrated with the mycobacteria growth indicator tube (MGIT) liquid culture employing a specially designed cross agarose channel for the tuberculosis chip. MGIT-, QMAC-, and Löwenstein-Jensen (LJ)-DSTs were performed using 13 drugs. The protocol for QMAC-DST was optimized using the inoculum obtained after the disaggregation of Mycobacterium tuberculosis clumps in MGIT culture. The completion times of QMAC-DST and MGIT-DST were analyzed, and the results of all three DSTs were compared. Discrepant results were analyzed using line probe assays and DNA sequencing. Nontuberculous mycobacteria were distinguished using the ρ-nitrobenzoic acid inhibition test. The overall agreement rate of QMAT-DST and LJ-DST was 97.0% and that of QMAT-DST and MGIT-DST was 86.3%. An average turnaround time for DST was 5.4 days, which was considerably less than the time required for MGIT-DST. The overall time required to obtain DST results using QMAC-DST integrated with MGIT culture was an average of 18.6 days: 13.2 days for culture and identification and 5.4 days for DST. Hence, QMAC-DST integrated with liquid culture can be used to perform DSTs with short turnaround times and effective detection. KEY POINTS: • QMAC system can simultaneously perform phenotypic DST with 13 anti-TB drugs and PNB. • An optimized DST protocol led to a marked decrease in clumping in MGIT culture. • QMAC system integrated with MGIT liquid culture system reduced the turnaround time.
Keywords: MGIT-DST; Mycobacterium tuberculosis; Phenotypic drug susceptibility testing; QMAC system.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Banu S, Rahman SM, Khan MS, Ferdous SS, Ahmed S, Gratz J, Stroup S, Pholwat S, Heysell SK, Houpt ER (2014) Discordance across several methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a single laboratory. J Clin Microbiol 52:156–163. https://doi.org/10.1128/JCM.02378-13 - DOI - PubMed - PMC
-
- Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F (2010) Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol 48:300–301. https://doi.org/10.1128/JCM.01775-09 - DOI - PubMed
-
- Choi J, Yoo J, Kim KJ, Kim EG, Park KO, Kim H, Kim H, Jung H, Kim T, Choi M, Kim HC, Ryoo S, Jung YG, Kwon S (2016) Rapid drug susceptibility test of Mycobacterium tuberculosis using microscopic time-lapse imaging in an agarose matrix. Appl Microbiol Biotechnol 100:2355–2365. https://doi.org/10.1007/s00253-015-7210-0 - DOI - PubMed
-
- Chopra KK, Sidiq Z, Hanif M, Dwivedi KK (2020) Advances in the diagnosis of tuberculosis - journey from smear microscopy to whole genome sequencing. Indian J Tuberc 67:S61–S68. https://doi.org/10.1016/j.ijtb.2020.09.026 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical